Develops cancer drugs for colorectal and pancreatic cancers.
Jun 2026Revenue $508K/yrExpenses $42.8M/yr
No trendCash runway ≈ 10 months from Jun 2026
Figures by year
When will Cardiff Oncology be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $508K and expenses $42.8M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $593K | $49.6M | −$49.0M |
| Dec 2024 | $683K | $49.3M | −$48.7M |
| Dec 2023 | $488K | $45.9M | −$45.4M |
| Dec 2022 | $386K | $40.3M | −$39.9M |
| Dec 2021 | $359K | $29.2M | −$28.9M |
| Dec 2020 | $366K | $19.5M | −$19.1M |
| Dec 2019 | $245K | $16.9M | −$16.7M |
| Dec 2018 | $378K | $17.4M | −$17.1M |
| Dec 2017 | $505K | $26.1M | −$25.6M |
| Dec 2016 | $381K | $40.5M | −$40.1M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.